Expression of the membrane attack complex of complement and its inhibitors during human liver allograft transplantation

Journal of Hepatology

Volumn 27, Issue 5, 1997, Pages 881-889

  Conti, Filomena ^a   Grude, Pascale ^a   Calmus, Yvon ^a   Scoazec, Jean Yves ^b  

^a Hôpital Cochin ^*  (France)

^b INSERM   (France)

Author keywords

Acute rejection; Chronic rejection; Complement; Immunohistochemistry; Liver transplantation; Membrane attack complex of complement

Indexed keywords

AZATHIOPRINE; CD59 ANTIGEN; CLUSTERIN; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE; VITRONECTIN;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030696835     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80326-1     Document Type: Article

References (50)

1. Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Annu Rev Immunol. 4:1986;119-156.
2. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection - an undefined conundrum. Transplantation. 52:1991;389-398.
3. Auchincloss H Jr. Xenogeneic transplantation: a review. Transplantation. 46:1988;1-9.
4. van den Bogaerde J, Aspinall R, Wang M-W, Cary N, Lim S, Wright L, et al. Induction of long-term survival of hamster heart xenografts in rats. Transplantation. 52:1991;15-20.
5. Platt JL, Lindman BJ, Geller RL, Noreen HJ, Swanson JL, Dalmasso A, et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation. 52:1991;1037-1043.
6. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol. 132:1988;489-502.
7. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I response. I. Clinical and pathological features of anti-class I-mediated rejection. Transplantation. 49:1990;85-89.
8. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathological features of renal transplants with anti-class I-like antibody. Transplantation. 53:1992;550-556.
9. Feucht He, Schneeberger H, Hillebrand G. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43:1993;1333-1339.
10. Svalander C, Nyberg G, Blohme I, Eggertsen G, Nilsson B, Nilsson U. Acute early allograft failure and the C3/macrophage phenomenon. Transplant Proc. 25:1993;903.
11. Maisch B, Weyerer O, Hufnagel G, Hengstenberg C, Schönian U, Haverich A, et al. The vascular endothelium as target of humoral auto-reactivity in myocarditis and rejection. Z Kardiol. 78:1989;95-99.
12. Miller LW, Wesp A, Jennison SH. Vascular rejection in heart transplant recipients. J Heart Lung Transplant. 12:1993;S147-S152.
13. Hammond EH, Ensley RD, Yowell RL. Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. Transplant Proc. 23:1991;26-27.
14. Brauer RB, Baldwin WM III, Ibrahim S, Sanfilippo F. The contribution of terminal complement components to acute and hyperacute allograft rejection. Transplantation. 59:1995;288-293.
15. Schuurman HJ, Meyling FH, Wijngaard PL, van der Meulen A, Slootweg PJ. Endomyocardial biopsies after heart transplantation: the presence of immunoglobulin/immune complex deposits. Transplantation. 48:1989;435-439.
16. Zales VR, Crawford S, Becker CL, Lynch P, Benser W Jr, Mavroudis C. Spectrum of humoral rejection after pediatric heart transplantation. J Heart Lung Transplant. 12:1993;563-569.
17. Scoazec J-Y, Delautier D, Moreau A, Durand F, Degott C, Benhamou J-P, et al. Expression of complement regulatory proteins in normal and UW-preserved human liver. Gastroenterology. 107:1994;505-516.
18. Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol. 22:1985;183-195.
19. Murphy BF, Kirszbaum L, Walker ID, d'Apice AJF. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits of glomerulonephritis. J Clin Invest. 81:1988;1858-1864.
20. Graham RC Jr, Karnovsky MJ. The early stages of absorption of horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem. 14:1966;291-298.
21. Autschbach F, Meuer SC, Moebius U, Manns M, Hess G, Meyer zum Büschenfelde KH, et al. Hepatocellular expression of lymphocyte function-associated antigen-3 in chronic hepatitis. Hepatology. 14:1991;223-230.
22. Mosnier J-F, Scoazec J-Y, Marcellin P, Degott C, Benhamou J-P, Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic viral hepatitis C. Gastroenterology. 107:1994;1457-1468.
23. Polirhonis M, Machet D, Saunders J, O'Bryan M, McRae J, Murphy B. Immunohistological detection of C5b-9 complement complexes in normal and pathological human livers. Pathology. 25:1993;20-23.
24. Scoazec J-Y, Borghi-Scoazec G, Durand F, Bernuau J, Pham B-N, Belghiti J, et al. Complement activation after ischemia-reperfusion in human liver allografts: incidence and pathophysiological consequences. Gastroenterology. 112:1997;908-918.
25. Hinglais N, Kazatchkine MD, Bhakdi S, Appay M-D, Mandet C, Grossetete J, et al. Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int. 30:1986;399-410.
26. Falk RJ, Podack E, Dalmasso AP, Jennette JC. Localization of S-protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol. 127:1987;182-190.
27. Okada M, Yoshioka K, Takemura T, Akano N, Aya N, Murakami K, et al. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor. Virchows Arch A (Pathol Anat). 422:1993;367-373.
28. Tomino Y, Yagame M, Eguchi K, Nomoto Y, Sakai H. Immunofluorescent studies on S-protein in glomeruli from patients with IgA nephropathy. Am J Pathol. 129:1987;402-406.
29. Cosyns JP, Kazatchkine MD, Bhakdi S, Mandet C, Grossetete J, Hinglais N, et al. Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. Clin Nephrol. 26:1986;203-208.
30. Bariéty J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD. Immunohistochemical study of complement S protein (vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol. 75:1989;76-81.
31. Liu G, Butany J, Wanless IR, Cameron R, Greig P, Levy G. The vascular pathology of human hepatic allografts. Human Pathol. 24:1993;182-188.
32. Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 9:1989;204-209.
33. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation. 56:1993;69-75.
34. Takemura M, Oguma S, Mori S. Peribiliary vascular diseases in rejected livers: computer-aided three-dimensional reconstruction and morphometry. Transplant Proc. 23:1991;1409-1411.
35. Sanchez-Urdazpal L, Gores JG, Ward EM, Maus TP, Wahlstrom HE, Moore SB, Wiesner RH, Krom RAF. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology. 16:1992;49-53.
36. Scotté M, Dousset B, Calmus Y, Conti F, Houssin D, Chapuis Y. The influence of cold ischemia time on biliary complications following liver transplantation. J Hepatol. 21:1994;340-346.
37. Batts KP, Moore B, Perkins JD, Wiesner RH, Grambsch PM, Krom RAF. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation. 45:1988;376-379.
38. Donaldson PT, Alexander GJM, O'Grady J. Evidence for an immune response to HLA class I antigens in the vanishing bile duct syndrome after liver transplantation. Lancet. 1:1987;945.
39. Biesecker G. Membrane attack complex of complement as a pathologic mediator. Lab Invest. 49:1983;237-249.
40. Heideman M. Complement activation in vitro induced by endotoxin and injured tissue. J Surg Res. 26:1979;670-673.
41. Seifert PS, Catalfamo JL, Dodds J. Complement activation after aortic endothelial injury. Semin Thromb Haemost. 12:1986;280-291.
42. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 13:1991;882-891.
43. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol. 19:1995;192-206.
44. Vierling JM, Fennell RH. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology. 5:1985;1076-1082.
45. Uesu T, Mizuno M, Inoué H, Tomoda J, Tsuji T. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest. 72:1995;587-592.
46. Tandon N, Morgan BP, Weetman AP. Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology. 75:1992;372-377.
47. Ashgar SS. Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest. 72:1995;254-271.
48. Moutabarrik A, Nakanishi I, Namiki M, Hara T, Matsumoto M, Okuyama A. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46 (MCP), CD55 (DAF) and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res. 12:1993;167-172.
49. Zhao J, Rollins SA, Maher SE, Bothwell ALM, Sims PJ. Amplified gene expression in CD59-transfected chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem. 266:1991;13418-13422.
50. Bjørge L, Vedeler CA, Ulvestad E, Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol. 24:1994;1597-1603.